Apitoria Pharma Private Limited – FDA 483, Aug 29, 2025

An FDA inspection of Apitoria Pharma Private Limited, Unit 1, located in Doullabad, Telangana, India, identified significant deviations from good manufacturing practices, with observations referencing dates as recent as December 2024. The FDA Form 483, issued on August 29, 2025, details several critical issues. Main violations include inadequate investigations into out-of-specification (OOS) results for intermediate and active pharmaceutical ingredient (API) batches, failing to determine root causes effectively. Process validation was deemed insufficient, lacking assurance that manufacturing processes consistently produce materials meeting quality specifications. The quality unit also failed to properly review and approve critical quality documents, specifically lacking audit trail reviews prior to batch release, even for products shipped to the US market. Additionally, equipment qualification for manufacturing blenders was found deficient, demonstrating a lack of consistent performance under operating conditions or established critical process parameters. Finally, laboratory controls were criticized for not having scientifically sound and appropriately validated analytical test procedures, particularly for HPLC assay and related substances methods, including issues with sample preparation techniques. Apitoria Pharma is required to provide a comprehensive response detailing corrective and preventive actions to address these serious regulatory deficiencies.